Comera Life Sciences Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
CMRA
- Investments
-
1
- Share Price
-
$0.02
- (As of Tuesday Closing)
Comera Life Sciences General Information
Description
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Contact Information
Website
www.comeralifesciences.comCorporate Office
- 12 Gill Street
- Suite 4650
- Woburn, MA 01801
- United States
Corporate Office
- 12 Gill Street
- Suite 4650
- Woburn, MA 01801
- United States
Comera Life Sciences Timeline
Comera Life Sciences Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $0.02 - $0.74 | $682K | 30.7M | 12.8K | -$0.22 |
Comera Life Sciences Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 13,396 | 26,544 | ||
| Revenue | 1,000 | 633 | 320 | 443 |
| EBITDA | (8,884) | (17,890) | (5,366) | (2,036) |
| Net Income | (9,009) | (18,004) | (5,452) | (2,125) |
| Total Assets | 3,072 | 3,727 | 7,418 | 546 |
| Total Debt | 172 | 319 | 323 | 161 |
Comera Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Comera Life Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Comera Life Sciences Comparisons
Industry
Financing
Details
Comera Life Sciences Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Locus Biosciences | Venture Capital-Backed | Morrisville, NC | ||||
| Arecor Therapeutics | Formerly VC-backed | Little Chesterford, United Kingdom | ||||
| Athos Therapeutics | Venture Capital-Backed | Torrance, CA | ||||
| Lindy Biosciences | Venture Capital-Backed | Morrisville, NC | ||||
| Landos Biopharma | Formerly VC-backed | Blacksburg, VA |
Comera Life Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Comera Life Sciences Patents
Comera Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4210757-A2 | Excipient compounds for protein formulations | Pending | 11-Sep-2020 | ||
| EP-4065166-A1 | Excipient compounds for biopolymer formulations | Pending | 26-Nov-2019 | ||
| CA-3159377-A1 | Excipient compounds for biopolymer formulations | Pending | 26-Nov-2019 | ||
| EP-4065166-A4 | Excipient compounds for biopolymer formulations | Pending | 26-Nov-2019 | ||
| EP-3886909-A1 | Excipient compounds for protein processing | Pending | 29-Nov-2018 | C07K16/244 |
Comera Life Sciences Executive Team (9)
| Name | Title | Board Seat |
|---|---|---|
| Jeffrey Hackman | Chairman & Chief Executive Officer | |
| Michael Campbell | Executive Vice President and Chief Financial Officer | |
| Robert Mahoney Ph.D | Chief Scientific Officer | |
| Janice McCourt | Executive | |
| David Soane Ph.D | Co-Founder |
Comera Life Sciences Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barbara Finck MD | Self | Member of the Scientific Advisory Board | |
| Edward Sullivan | Self | Board Member | |
| James Sherblom | Self | Board Member | |
| Jeffrey Hackman | Comera Life Sciences | Chairman & Chief Executive Officer | |
| John Sorvillo Ph.D | Comera Life Sciences | Chairman of Scientific Advisory Board |
Comera Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Comera Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Comera Life Sciences Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| OTR Acquisition | 19-May-2022 | Special Purpose Acquisition Company (SPAC) |
Comera Life Sciences FAQs
-
When was Comera Life Sciences founded?
Comera Life Sciences was founded in 2014.
-
Who is the founder of Comera Life Sciences?
Zachariah Jonasson Ph.D and David Soane Ph.D are the founders of Comera Life Sciences.
-
Who is the CEO of Comera Life Sciences?
Jeffrey Hackman is the CEO of Comera Life Sciences.
-
Where is Comera Life Sciences headquartered?
Comera Life Sciences is headquartered in Woburn, MA.
-
What is the size of Comera Life Sciences?
Comera Life Sciences has 16 total employees.
-
What industry is Comera Life Sciences in?
Comera Life Sciences’s primary industry is Biotechnology.
-
Is Comera Life Sciences a private or public company?
Comera Life Sciences is a Public company.
-
What is Comera Life Sciences’s stock symbol?
The ticker symbol for Comera Life Sciences is CMRA.
-
What is the current stock price of Comera Life Sciences?
As of 16-Jul-2024 the stock price of Comera Life Sciences is $0.02.
-
What is the current market cap of Comera Life Sciences?
The current market capitalization of Comera Life Sciences is $682K.
-
What is Comera Life Sciences’s current revenue?
The trailing twelve month revenue for Comera Life Sciences is $1M.
-
Who are Comera Life Sciences’s competitors?
Locus Biosciences, Arecor Therapeutics, Athos Therapeutics, Lindy Biosciences, and Landos Biopharma are some of the 8 competitors of Comera Life Sciences.
-
What is Comera Life Sciences’s annual earnings per share (EPS)?
Comera Life Sciences’s EPS for 12 months was -$0.22.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
